Categories: Clinical TrialNews

Essex Management Appoints David Loose as Chief Executive Officer

Appointment Reflects Commitment to Continuing Essex’s Strategic Vision

ROCKVILLE, Md., Jan. 7, 2025 /PRNewswire/ — Essex Management, an Emmes Group company and a leader in biomedical informatics and health information technology, is pleased to announce the appointment of David Loose as Chief Executive Officer (CEO), effective immediately. David succeeds Kevin Hurley, who has served as CEO since February 2019 and will transition to the role of Executive Advisor.

David Loose joined Essex Management as a partner in February 2009 and has played a pivotal role in the company’s growth. Starting as Vice President for Business Operations and Development, he later served as Chief Business Officer, overseeing critical operations, driving client-focused innovation, and delivering strategic initiatives such as NCI’s Clinical Trials Reporting Program (CTRP). His leadership and dedication to Essex’s mission have been instrumental in building its reputation as a trusted partner in the biomedical and health technology sectors.

“David’s leadership and dedication to Essex’s mission make him the ideal choice to guide the company forward,” said Sastry Chilukuri, CEO of Emmes Group. “His focus on innovation and client success will ensure Essex continues to deliver transformative solutions in biomedical informatics and health IT.”

Essex also recognizes Kevin Hurley’s significant contributions since joining the company in 2009. As a founding partner and later as CEO, Kevin guided Essex through transformative milestones, including its acquisition by Emmes Group in 2023. “We are deeply grateful for Kevin’s leadership and dedication over the years,” said David Loose. “His vision has been instrumental in Essex‘ success, and we’re fortunate to have his continued guidance as an Executive Advisor.”

Founded in 2009 and headquartered in Rockville, Maryland, Essex Management brings together multidisciplinary teams of engineers, business analysts, and project managers with computational biologists and clinical experts. Together, they deliver innovative health and biomedical information solutions for federal agencies, research institutions, and private-sector clients.

Under David Loose’s leadership, Essex Management is poised to build on its legacy of navigating the complexities of scientific computing to save lives and improve the quality of care.

About Emmes Group:
Emmes Group, a specialty, technology and AI enabled contract research organization (CRO), is advancing and modernizing clinical research to improve patient outcomes. Founded as Emmes more than 47 years ago, we became a trusted clinical research partner to the U.S. government. Today, Emmes Group is a global full-service CRO operating in 72 countries worldwide collaborating with government agencies, public-private partnerships, and biopharma innovators. Now wholly owned by New Mountain Capital, we are transforming the future of clinical research and bringing life-changing treatments closer to patients. Where human intelligence meets artificial intelligence. Learn more at www.theemmesgroup.com.

About Essex Management:
Essex Management, an Emmes Group company, is a biomedical informatics and health information technology firm that provides tailored consulting services and advanced technology solutions. Since 2009, Essex has strategically developed and managed complex health and biomedical information programs for the Federal Government, research academia, and private sectors. Headquartered in Rockville, MD, Essex Management is committed to saving lives and improving the quality of care through innovative solutions. Learn more at www.essexmanagement.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/essex-management-appoints-david-loose-as-chief-executive-officer-302343758.html

SOURCE Emmes Group

Staff

Recent Posts

MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi

KARACHI, Pakistan, Dec. 22, 2025 /PRNewswire/ -- MindHYVE.ai, Inc., and Khoja (Pirhai) Shia Isna Asheri Jamaat…

58 minutes ago

Castle Connolly Names Dr. Meegan Gruber, MD, PhD a 2026 Exceptional Woman in Medicine; Recognition to Be Featured in New York Magazine

Board-certified plastic surgeon and surgeon-scientist honored for clinical excellence, leadership, and commitment to patient education. …

58 minutes ago

Planning Time Off in 2026: Dr. Meegan Gruber, MD, PhD Releases a Recovery-Logistics Guide for Busy Professionals Considering Plastic Surgery

New "Recovery Logistics" checklist helps patients coordinate work, childcare, travel, and follow-up support-before they choose…

58 minutes ago

How to Choose a Plastic Surgeon in 2026: Dr. Meegan Gruber, MD, PhD Releases a Tampa Bay Patient Safety Checklist

Board-certified plastic surgeon shares a practical, question-based guide to help patients verify credentials, facility standards,…

58 minutes ago

Facelift + Eyelid Surgery in Tampa: Gruber Plastic Surgery Shares 2025 Planning Insights on Natural Results and Popular Procedure Pairings

ASPS trend reporting highlights facelift combined with eyelid surgery as a leading 2025 combination; national…

59 minutes ago

CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD

SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI)…

4 hours ago